ClinConnect ClinConnect Logo
Search / Trial NCT06633003

Effects of Oral Administration of Antrodia Cinnamomea Products for Clinical Symptoms in Spinocerebellar Ataxia Patients

Launched by ALPS BIOTECH CO. LTD · Oct 7, 2024

Trial Information

Current as of August 28, 2025

Recruiting

Keywords

Neuroinflammatory Diseases Nervous System Diseases Spinocerebellar Ataxia Antrodia Cinnamomea

ClinConnect Summary

This clinical trial is studying the effects of a natural product called Antrodia cinnamomea on patients with Spinocerebellar Ataxia, a condition that affects coordination and balance. The goal is to see if this product can help improve the symptoms associated with this disease. The trial is currently looking for participants aged between 30 and 70 years who are native Chinese speakers and have been diagnosed with Spinocerebellar Ataxia. To be eligible, participants should have a specific score indicating their level of symptoms and must be able to read, write, and communicate in Chinese.

If you decide to participate, you can expect to take Antrodia cinnamomea products and report on any changes in your symptoms. However, there are some important factors to consider; for example, individuals with serious health issues, pregnant or breastfeeding women, and those who have recently taken similar products may not qualify for this study. This trial could be significant for understanding how to better manage neurodegenerative diseases, and your involvement might contribute to important findings that could help others in the future.

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • 1. Adults aged 30 to 70 years, whose native language is Chinese.
  • 2. Patients diagnosed with Spinocerebellar Ataxia.
  • 3. Subjects with a score below 30 on the Scale for the Assessment and Rating of Ataxia (SARA scale).
  • 4. Individuals who can read and write in Chinese and communicate in Chinese.
  • 5. Agree to participate in the study.
  • Exclusion Criteria:
  • 1. Patients with severe systemic diseases, such as heart or respiratory failure, liver or kidney failure, severe brain injury, prolonged bed rest, or incurable malignancies.
  • 2. Pregnant women and breastfeeding mothers.
  • 3. Patients who have taken Antrodia cinnamomea products within the last 6 months prior to the trial.
  • 4. Patients with other factors that prevent them from continuing to participate in this study.

About Alps Biotech Co. Ltd

Alps Biotech Co., Ltd. is a leading biopharmaceutical company dedicated to advancing innovative therapies and solutions in the field of healthcare. With a strong focus on research and development, Alps Biotech specializes in the discovery and commercialization of novel biologics and pharmaceuticals aimed at addressing unmet medical needs. The company leverages cutting-edge technology and a robust pipeline of clinical trials to drive the development of effective treatments across various disease areas. Committed to quality and compliance, Alps Biotech collaborates with global partners to enhance patient outcomes and contribute to the advancement of medical science.

Locations

Taipei, , Taiwan

Patients applied

0 patients applied

Trial Officials

MingChe Kuo

Principal Investigator

National Taiwan University

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported